SPHK1 and glioblastoma: Furthermore, previous studies have found that SPHK1 overexpression is a prognostic biomarker for the survival of patients with glioblastoma [10], head and neck cancer [6], salivary duct cancer [22], esophageal cancer [27], gastric cancer [7], and colorectal cancer [28].